

Date: 07/07/2025
Our Ref: 10165
Enquiries to loth.freedomofinformation@nhs.scot

Dear

FREEDOM OF INFORMATION – BREAST CANCER TREATMENT

I write in response to your request for information in relation to breast cancer treatment in NHS Lothian.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Answer:

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	87
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	0
1.4 Fulvestrant (fulvestrant or Faslodex)	61
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	56
1.7 Ribociclib (Kisqali)	67
1.8 Capivasertib (Truqap)	0
1.9 Talazoparib (Talzenna)	≤5
1.10 Olaparib (Lynparza)	23

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information

(Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Question:

2. How many patients received the following medicines for early breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Answer:

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	≤5
2.2 Ribociclib (Kisqali)	0
2.3 Olaparib (Lynparza)	0

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Question:

3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?

Answer:

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	66
3.2 Ribociclib (Kisqali)	≤5

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Question:

4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?

Answer:

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	7
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	0
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	17

Question:

5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?

Answer:

Type of breast cancer	Number patients treated
5.1 All types of breast cancer	≤5
5.2 Locally advanced or metastatic breast cancer	≤5

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Question:

6. How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	71

6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	60
6.4 Trastuzumab Deruxtecan (EnHertu)	28
6.5 Trastuzumab Emtansine (Kadcyla)	22
6.6 Tucatinib (Tukysa)	≤5
6.7 Neratinib (Nerlynx)	≤5

I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Question:

7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50*, D509*) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	54
7.2 Trastuzumab Deruxtecan (EnHertu)	28

Question:

8. How many patients received the following products with curative treatment intent in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Answer:

Treatment intent	Number patients treated
8.1 Pertuzumab (Perjeta)	0
8.2 Pertuzumab with Trastuzumab (Phesgo)	37
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	68

8.4 Trastuzumab Emtansine (Kadcyla)

13

Question:

9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Answer:

This information is not collected centrally. We are only able to divide by curable and non curable. Information may be held in individual patient records, but in order to provide the information you request it would be necessary to review each patient record over the period you have specified, requiring significant resources. Under section 12 of the Freedom of Information (Scotland) Act 2002, NHS Lothian is not required to respond to your request if the resources required to do so equate to more than £600 in cost.

Question:

10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?

Answer:

This data is not available.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive